The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy children aged 2 to 6 years in China.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
50
GSK Investigational Site
Liucheng County, Guangxi, China
Occurrence of each solicited symptom
Time frame: Within the 8-day (Day 0 - Day 7) follow-up period after the vaccine dose.
Occurrence of unsolicited adverse events
Time frame: Within the 31 days (Day 0 - Day 30) after the vaccine dose.
Occurrence of serious adverse events
Time frame: Throughout the study period following the vaccine dose.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.